TY - JOUR
T1 - Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in asian people
T2 - A nationwide population-based study
AU - Hong, Chien Tai
AU - Chan, Lung
AU - Hu, Chaur Jong
AU - Lin, Chien Min
AU - Hsu, Chien Yeh
AU - Lin, Ming Chin
N1 - Publisher Copyright:
© 2017 Korean Breast Cancer Society. All rights reserved.
PY - 2017/12
Y1 - 2017/12
N2 - Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.
AB - Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.
KW - Breast neoplasms
KW - Parkinson disease
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=85039747565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039747565&partnerID=8YFLogxK
U2 - 10.4048/jbc.2017.20.4.356
DO - 10.4048/jbc.2017.20.4.356
M3 - Article
AN - SCOPUS:85039747565
SN - 1738-6756
VL - 20
SP - 356
EP - 360
JO - Journal of Breast Cancer
JF - Journal of Breast Cancer
IS - 4
ER -